@2024 Afarand., IRAN
ISSN: 2252-0805 The Horizon of Medical Sciences 2013;19(2):71-76
ISSN: 2252-0805 The Horizon of Medical Sciences 2013;19(2):71-76
Effect of Verapamil on Ivermectin Concentration of Dog Serum and Cerebro-spinal Fluid
ARTICLE INFO
Article Type
Original ResearchAuthors
Najafzadeh H. (*)Avizeh R. (1)
Kavousi N. (2)
(*) Department of Pharmacology & Toxicology, Faculty of Veterinary Medicine, Shahid-Chamran University, Ahvaz, Iran
(1) Department of Clinical Pathology, Faculty of Veterinary Medicine, Shahid-Chamran University, Ahvaz, Iran
(2) Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid-Chamran University, Ahvaz, Iran
Correspondence
Address: Department of Pharmacology, Faculty of Veterinary Medicine, Shahid-Chamran University, Golestan Boulevard, Ahvaz, Iran.Phone: +986113330073
Fax: +986113336087
najafzadeh@scu.ac.ir
Article History
Received: August 16, 2012Accepted: June 18, 2013
ePublished: June 25, 2013
BRIEF TEXT
CITIATION LINKS
[1] Adams HR. Vrerinary pharmacology and therapeutics. 8th ed. Iowa: Iowa State University Press; 2001.
[2] Mealey KL. Canine ABCB1 and macrocyclic lactones: Heartworm prevention and pharmacogenetics. Vet Parasitol. 2008;158(3):215-22.
[3] Bissonnette S, Paradis M, Daneau I, Silversides DW. The ABCB1-1 Delta mutation is not responsible for subchronic neurotoxicity seen in dogs of non-collie breeds following macrocyclic lactone treatment for generalized demodicosis. Vet Dermatol. 2009;20(1):60-6.
[4] Warrington Jill S, Greenblatt DJ, von Moltke L. The effect of age on p-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther. 2004;309(2):730-6.
[5] Ambudkar SV, Kimchi-Sarfaty C, Suna ZE, Gottesman M. P-glycoprotein: From genomics to mechanism. Oncogene. 2003;22(47):7468-85.
[6] Fardel O, Lecureur V, Loyer P, Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol. 1995;49(9):1255-60.
[7] El-Ashmawy IM, El-Nahas AF, Bayad AE. Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor. Res Vet Sci. 2011;90(1):116-23.
[8] El-Nahas AF, El-Ashmawy IM. Effect of ivermectin on male fertility and its interaction with P-glycoprotein inhibitor (verapamil) in rats. Environ Toxicol Pharmacol. 2008;26(2):206-11.
[9] Gokbulut C, Karademir U, Boyacioglu M, McKellar QA. Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol. 2006;135(3-4):347-54.
[10] Prieto JG, Merino G, Pulido MM, Estevez E, Molina AJ, Vila AL, et al. Improved LC method to determine ivermectin in plasma. J Pharmaceut Biomed Anal. 2003;31(4):639-45.
[11] Bartels AL, Kortekaas R, Bart J, Willemsen A, Klerk OL, Vries J, et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neurobiol Aging. 2008;30(11):1818-24.
[12] Hendrikse NH, Bart J, de Vries EG, Groen HJ, van der Graaf WT, Vaalburg W. P-glycoprotein at the blood- brain barrier and analysis of drug transport with positron-emissien tomography. J Clin Pharmacol. 2001;1:48-54.
[13] Hopper K, Aldrich J, Haskins SC. Ivermectin toxicity in 17 collies. J Vet Inter Med. 2002;16(1):89-94.
[14] Lespine A, Dupuy J, Alvinerie M, Comera C, Nagy T, Krajcsi P, et al. Interaction of macrocyclic lactones with the multidrug transporters: The bases of the pharmacokinetics of lipid-like drugs. Curr Drug Metabol. 2009;10(3):272-88.
[15] El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The effect of azithromycin on ivermectin pharmacokinetics: A population pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008;2(5):236.
[16] Gonzalez Canga A, Sahagun Prieto AM, Jose Diez Liebana M, Martinez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J. 2009;179(1):25-37.
[17] Eraslan G, Kanbur M, Liman BC, Cam Y, Karabacak M, Altinordulu S. Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs. Food Chem Toxicol. 2010;48(8-9):2181-5.
[18] Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc. 2008;233(6):921-4.
[19] Han JI, Son HW, Park SC, Na KJ. Novel insertion mutation of ABCB1 gene in an ivermectin-sensitive Border Collie. J Vet Sci. 2010;11(4):341-4.
[20] Wang JC, Liub XY, Lu WL, Chang A, Zhang Q, Goh BC, et al. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur J Pharm Biopharm. 2008;62(1):44-51.
[21] Mankhetkorn S, Teodori E, Garnier-Suillerot A. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue. Chem Biol Int. 1999;121:125-40.
[22]Bansal T, Mishra G, Jaggi M, khar RK, Talegaokar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009;36(4-5):580-90.
[23] Lemma Gl, Wong Z, Hamman MA, Zaherr NA, Groski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome p4503 A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79(3):218-30.
[24] Marier JF, Deschenes JL, Hage A, Seliniotakis E, Gritsas A, Flarakos T, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gP inhibitor verapamil. Life Sci. 2005;77(23):2911-26.
[25] Neuhaus W, Stessl M, Strizsik E, Bennani-Baiti B, Wirth M, Stefan Toegel S, et al. Blood-brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein. Neurosci Lett. 2010;469(2):224-8.
[26] Ballent M, Lifschitz A, Virkel G, Mate L, Lanusse C. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. J Vet Pharmacol Ther. 2010;33(3):252-9.
[27] Bates N, Chatterton J, Robbins C, Wells K, Hughes J, Stone M, Campbell A. Lipid infusion in the management of poisoning: A report of 6 canine cases. Vet Rec. 2013;172(13):339.
[28] Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of Pglycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(2):313-33.
[29] Conen S, Theunissen EL, Vermeeren A, van Ruitenbeek P, Stiers P, Mehta MA, et al. The role of P-glycoprotein in CNS antihistamine effects. Psychopharmacology (Berl). 2013. [Epub ahead of print]
[2] Mealey KL. Canine ABCB1 and macrocyclic lactones: Heartworm prevention and pharmacogenetics. Vet Parasitol. 2008;158(3):215-22.
[3] Bissonnette S, Paradis M, Daneau I, Silversides DW. The ABCB1-1 Delta mutation is not responsible for subchronic neurotoxicity seen in dogs of non-collie breeds following macrocyclic lactone treatment for generalized demodicosis. Vet Dermatol. 2009;20(1):60-6.
[4] Warrington Jill S, Greenblatt DJ, von Moltke L. The effect of age on p-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther. 2004;309(2):730-6.
[5] Ambudkar SV, Kimchi-Sarfaty C, Suna ZE, Gottesman M. P-glycoprotein: From genomics to mechanism. Oncogene. 2003;22(47):7468-85.
[6] Fardel O, Lecureur V, Loyer P, Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol. 1995;49(9):1255-60.
[7] El-Ashmawy IM, El-Nahas AF, Bayad AE. Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor. Res Vet Sci. 2011;90(1):116-23.
[8] El-Nahas AF, El-Ashmawy IM. Effect of ivermectin on male fertility and its interaction with P-glycoprotein inhibitor (verapamil) in rats. Environ Toxicol Pharmacol. 2008;26(2):206-11.
[9] Gokbulut C, Karademir U, Boyacioglu M, McKellar QA. Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol. 2006;135(3-4):347-54.
[10] Prieto JG, Merino G, Pulido MM, Estevez E, Molina AJ, Vila AL, et al. Improved LC method to determine ivermectin in plasma. J Pharmaceut Biomed Anal. 2003;31(4):639-45.
[11] Bartels AL, Kortekaas R, Bart J, Willemsen A, Klerk OL, Vries J, et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neurobiol Aging. 2008;30(11):1818-24.
[12] Hendrikse NH, Bart J, de Vries EG, Groen HJ, van der Graaf WT, Vaalburg W. P-glycoprotein at the blood- brain barrier and analysis of drug transport with positron-emissien tomography. J Clin Pharmacol. 2001;1:48-54.
[13] Hopper K, Aldrich J, Haskins SC. Ivermectin toxicity in 17 collies. J Vet Inter Med. 2002;16(1):89-94.
[14] Lespine A, Dupuy J, Alvinerie M, Comera C, Nagy T, Krajcsi P, et al. Interaction of macrocyclic lactones with the multidrug transporters: The bases of the pharmacokinetics of lipid-like drugs. Curr Drug Metabol. 2009;10(3):272-88.
[15] El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The effect of azithromycin on ivermectin pharmacokinetics: A population pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008;2(5):236.
[16] Gonzalez Canga A, Sahagun Prieto AM, Jose Diez Liebana M, Martinez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J. 2009;179(1):25-37.
[17] Eraslan G, Kanbur M, Liman BC, Cam Y, Karabacak M, Altinordulu S. Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs. Food Chem Toxicol. 2010;48(8-9):2181-5.
[18] Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc. 2008;233(6):921-4.
[19] Han JI, Son HW, Park SC, Na KJ. Novel insertion mutation of ABCB1 gene in an ivermectin-sensitive Border Collie. J Vet Sci. 2010;11(4):341-4.
[20] Wang JC, Liub XY, Lu WL, Chang A, Zhang Q, Goh BC, et al. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur J Pharm Biopharm. 2008;62(1):44-51.
[21] Mankhetkorn S, Teodori E, Garnier-Suillerot A. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue. Chem Biol Int. 1999;121:125-40.
[22]Bansal T, Mishra G, Jaggi M, khar RK, Talegaokar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009;36(4-5):580-90.
[23] Lemma Gl, Wong Z, Hamman MA, Zaherr NA, Groski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome p4503 A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79(3):218-30.
[24] Marier JF, Deschenes JL, Hage A, Seliniotakis E, Gritsas A, Flarakos T, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gP inhibitor verapamil. Life Sci. 2005;77(23):2911-26.
[25] Neuhaus W, Stessl M, Strizsik E, Bennani-Baiti B, Wirth M, Stefan Toegel S, et al. Blood-brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein. Neurosci Lett. 2010;469(2):224-8.
[26] Ballent M, Lifschitz A, Virkel G, Mate L, Lanusse C. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. J Vet Pharmacol Ther. 2010;33(3):252-9.
[27] Bates N, Chatterton J, Robbins C, Wells K, Hughes J, Stone M, Campbell A. Lipid infusion in the management of poisoning: A report of 6 canine cases. Vet Rec. 2013;172(13):339.
[28] Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of Pglycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(2):313-33.
[29] Conen S, Theunissen EL, Vermeeren A, van Ruitenbeek P, Stiers P, Mehta MA, et al. The role of P-glycoprotein in CNS antihistamine effects. Psychopharmacology (Berl). 2013. [Epub ahead of print]